Recombinant Human EPO
EPO is predominantly synthesized and secreted by tubular and juxtatubular capillary, endothelial, and interstitial cells of the kidney. Approximately 10-15% of the total amount of EPO comes from extrarenal sources and is predominantly produced by hepatocytes and Kupffer cells of the liver. Approximately 40% of the molecular mass of EPO is due to its glycosylation. Glycosylation is an important factor determining the pharmacokinetic behaviour of EPO in vivo. Non-glycosylated Epo has an extremely short biological half life. Recombinant Human EPO is a glycosylated protein that runs at approximately 35 kDa owing to its glycosylation.
Product Specifications
CAS Number
9000-83-3
Gene Name
EPO
Gene Aliases
Erythropoietin<br/>Recombinant Human Erythropoietin-Alpha (EPO)
Gene ID
2056
Accession Number
P01588
Organism
Human
Source
CHO
Concentration
<1.0 EU/μg of recombinant protein as determined by the LAL method
Purity
>95% as determined by SDS-PAGE
Solubility
Function
Molecular Weight
20
Shipping Conditions
Ambient Temperature
Storage Conditions
Appearance
Lyophilized Powder
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS (pH 7)
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Anti-Smad9 Antibody Picoband®, Dylight594 Conjugate